Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

st can be accessed by logging onto http://www.biocryst.com. Please connect to the Web site at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardiovascular, and autoimmune disease targets, to create long-term sustainable value. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein in
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - JSS Medical Research Inc., ... announced today that it concluded the acquisition of Max Neeman International ... . Additional regional offices are located in Ahmedabad, Bangalore ... . Through a US subsidiary, a regional office is located ... international expansion is supported by the recent equity investment transaction into ...
(Date:5/4/2015)... 4, 2015 GliaCure, a privately-held biotechnology ... for neurological and neuropsychiatric disorders based on glial ... Alzheimer,s patients in a Phase 1b clinical trial ... developed as a potential disease-modifying treatment. GliaCure,s innovative ... that it both promotes the clearance of amyloid ...
(Date:5/4/2015)... STONY BROOK, N.Y. , May 4, 2015 ... executed a $250,000 cooperative research and development agreement ... ) to advance the development of TRB-N0224 for ... companion animals, including dogs and cats.  Traverse Biosciences ... sublicense TRB-N0224 for the treatment and control of ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - The Fight Against ... pleased to announce the formation of Turnstone Biologics ... treatments for cancer that harness the patient,s own ... unique collaboration between the Children,s Hospital of ... McMaster University, the Ontario Institute for Cancer Research ...
Breaking Biology Technology:JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3
... Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer ... human amniotic membrane, announced today its results for the ... The Company recorded record revenue for the ... quarter of 2011 revenue of $1,043,000 and a six-fold ...
... Pa., July 22, 2011 Janssen Biotech, Inc. ... Administration (FDA) issued a Complete Response letter for ... (golimumab).  The application, filed in September 2010, seeks ... inhibiting the progression of structural damage, inducing major ...
... Inc. (Nasdaq: NGSX ), a biopharmaceutical company ... that on July 21, 2011 it entered into a ... to a group of institutional accredited investors and, subject ... $20 million in gross proceeds from the sale of ...
Cached Biology Technology:MiMedx Group Announces Second Quarter 2011 Results 2MiMedx Group Announces Second Quarter 2011 Results 3MiMedx Group Announces Second Quarter 2011 Results 4MiMedx Group Announces Second Quarter 2011 Results 5MiMedx Group Announces Second Quarter 2011 Results 6MiMedx Group Announces Second Quarter 2011 Results 7MiMedx Group Announces Second Quarter 2011 Results 8MiMedx Group Announces Second Quarter 2011 Results 9MiMedx Group Announces Second Quarter 2011 Results 10FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 2FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 3FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 4FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 5FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application 6NeurogesX, Inc. Announces $20 Million Private Placement 2NeurogesX, Inc. Announces $20 Million Private Placement 3NeurogesX, Inc. Announces $20 Million Private Placement 4
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... objects is one of the ultimate challenges in neuroscience. ... of Technology, launched an initiative with the hopes of shedding ... of his "Project Prakash" is to find, treat, and study ... that resulted from this project appears in the December 2006 ...
... shows that more people were at risk of anthrax infection ... office than previously known. The research is published in the ... available online. On the other hand, the study shows, prompt ... against the disease. , In October of 2001, a letter ...
... struggle with the heartache of infertility. Now there is the ... mutation in a gene that causes male infertility in mice. ... that leads specifically to infertility in a mammal has been ... mutations in the DNA of infertile men. , "If you ...
Cached Biology News:Anthrax attack posed greater potential threat than thought 2Researchers find gene mutation that causes infertility in male mice 2
... GEMINI is Tecan's pipetting software for ... GENESIS Freedom and the GENESIS WORKSTATION instruments ... intuitive software enables the user the simple ... of pipetting scripts. With the powerful scripting ...
... Expression is a revolutionary new application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
...
... Partek Genomics Solution is a ... interactive data visualization specifically designed to ... Designed for high-dimensional genomic studies containing ... is fast, memory efficient and will ...
Biology Products: